// App-Quantinova.ai

: Patient-Reported Outcomes from a Phase 2, Randomized Trial Evaluating the Safety and Efficacy of Pozelimab and Cemdisiran in Patients with Paroxysmal Nocturnal Hemoglobinuria

Researchers

Presenter

  • Chris Hartford

Principal Investigators

  • Bradley Dain

  • Steven Sherman

  • Yi Zhang

  • Rodrigo Pavani

  • Lisa Aurand

  • Diana Rofail

  • Richard Kelly

Medical Centers

  • Department of Haematology, St James University Hospital, Leeds, United Kingdom

Locations

  • United States

  • United Kingdom

Companies

  • Regeneron Pharmaceut

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Blood/haematological Diseases

Disease

  • Paroxysmal nocturnal hemoglobinuria

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Randomized

  • Efficacy

  • Safety

  • Global

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved